13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001825034
Total reported value
$439.8M
$439.8M
11 檔
59.1%
The Q1 2025 SEC filing reveals that Euclidean Capital LLC held a total portfolio value of $439.8M, covering 11 public equity positions.
In Q1 2025, Euclidean Capital LLC adopted a defensive or profit-taking posture, trimming 3 positions and completely liquidating 10 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including INDA, VEU, FHTX) accounted for 59.1% of total reported equity market value during Q1 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | INDA | Ishares Msci India ETF | ETF-Other | 46.91% | -0.26% | — | |
| 2 | VEU | Vanguard Ftse All-world Ex-u | ETF-Other | 45.40% | -0.33% | +96.55% | |
| 3 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 2.16% | -0.17% | — | |
| 4 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 2.07% | -0.76% | — | |
| 5 | PMVP | Pmv Pharmaceuticals Inc | Stock-Other | 1.08% | -0.03% | — | |
| 6 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 0.86% | — | -99.54% | |
| 7 | ALEC | Alector Inc | Stock-Other | 0.60% | -0.12% | — | |
| 8 | SRZN | Surrozen Inc | Stock-Other | 0.38% | -0.13% | — | |
| 9 | ✓ | Rapt Therapeutics Inc | Stock-Other | 0.30% | — | — | |
| 10 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 0.22% | -0.01% | — | |
| 11 | SRZNW | Surrozen Inc-cw25 | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | FHTX | Foghorn Therapeutics Inc | -1% | — | Add |
| 2 | ORIC | Oric Pharmaceuticals Inc | -2.1% | — | Trim |
| 3 | ALEC | Alector Inc | -4.2% | — | Add |
| 4 | ✓ | Rapt Therapeutics Inc | -5.2% | — | Trim |
| 5 | PMVP | Pmv Pharmaceuticals Inc | -30.1% | — | Trim |
| 6 | INDA | Ishares Msci India ETF | — | NEW | New buy |
| 7 | VEU | Vanguard Ftse All-world Ex-u | — | NEW | New buy |
| 8 | ✓ | — | EXIT | Sold out | |
| 9 | NGMUSD | Ngm Biopharmaceuticals Inc | — | EXIT | Sold out |
| 10 | DNLI | Denali Therapeutics Inc | — | EXIT | Sold out |
| 11 | CNST | Constellation Pharmaceutical | — | EXIT | Sold out |
| 12 | SNOW | Snowflake Inc | — | EXIT | Sold out |
| 13 | FFBC | First Financial Bancorp | — | EXIT | Sold out |
| 14 | NRIX | Nurix Therapeutics Inc | — | EXIT | Sold out |
| 15 | BEAM | Beam Therapeutics Inc | — | EXIT | Sold out |
| 16 | SPY | Ss Spdr S&p 500 ETF Trust-us | — | NEW | New buy |
| 17 | PDD | Pdd Holdings Inc | — | EXIT | Sold out |
| 18 | VIR | Vir Biotechnology Inc | — | EXIT | Sold out |
| 19 | SRZN | Surrozen Inc | — | NEW | New buy |
| 20 | TNYA | Tenaya Therapeutics Inc | — | NEW | New buy |
| 21 | SRZNW | Surrozen Inc-cw25 | — | NEW | New buy |
According to official SEC Form 13F filings, Euclidean Capital LLC reported a total U.S. public equity portfolio value of $439.8M across 11 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
INDA
市值: $124.8M
Top Position Liquidated / Trimmed
前期市值: $119.7M
During Q1 2025, Euclidean Capital LLC's top holdings by market value included INDA (46.9%)、VEU (45.4%)、FHTX (2.2%). The largest single position, INDA, represented 46.9% of total portfolio value.
In Q1 2025, Euclidean Capital LLC made 21 total portfolio adjustments, initiating 6 new buys, adding to 2 positions, trimming 3 holdings, and fully liquidating 10 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.